Wuxi And Qiagen Form Biomarker Partnership In Shanghai
This article was originally published in PharmAsia News
Executive SummarySHANGHAI - WuXi Pharmatech, China's top contract research organization, and Qiagen, the leading global provider of sample and assay technologies, announced Jan. 11 that they reached an agreement to provide an integrated single solution for molecular biomarker development, validation and personalized healthcare targets for their respective client bases
You may also be interested in...
Qiagen forms JV with Shanghai Jiao Tong University for translational research to focus on biomarkers, diagnostics for developing drugs specifically for Asians.